Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

BIOSYENT INC V.RX

Sector: Healthcare | Sub-Sector: Drug Manufacturers - Major
Alternate Symbol(s):  BIOYF

Biosyent Inc is a life science company engaged in marketing of pharmaceutical products & manufacturing & marketing of non-chemical bio & health-friendly insecticides. It acquires or license products & commercializes technology to health & public safety.
Price: $11.10 | Change: $-0.08 | %Change: -0.72%
Volume: 48,994 | Day High/Low: 11.18/10.57 | 52 Week High/Low: 12.82/4.57
View modes: 
0 stars

RE:Poised for a great 2015, says Cantor Fitzgerald Canada

Thanks for that, Sir_H. By the way, if anyone hasn't yet seen the company's Q4 presentation, I highly recommend they do so.  Lots of interesting (and compelling) new info is contained therein.  rate and reply
0 stars

Poised for a great 2015, says Cantor Fitzgerald Canada

http://www.cantechletter.com/2015/02/biosyent-poised-great-2015-says-cantor-fitzgerald-canada/  rate and reply
0 stars

Definately on the buyout list

Though i'll take all cap appreciation. Been building a new base and on any news will reach the $12.50 - $13.50 range per many analyst targets. Even the big original believers like Smedley and...read more
0 stars

RE:RE:Congratulations

Easy, I am also long RX and EFN. Awesome day for RX. Its still a buy at this level in my books, I will be adding more. As for EFN, numbers look good, I am hoping it jumps to $17 or $16.50 on the news....read more
0 stars

RE:Congratulations

retired...I'm long efn..fingures crossed tonight  rate and reply
0 stars

RE:Congratulations

Whoever sold me those 500 shares @ 9.50 this am...gracias! Sometimes things just work out  rate and reply
3.5 stars

Congratulations

to the wise individuals who picked up more shares in the mid $9.00 range this morning. Must have been a few retail investors who reacted to the bashers and panicked. RX has a good looking future and...read more
1 star

RE:RE:RE:RE:RE:Diluted EPS up 69%

One of the concerns of the specialty pharmas has been if they can find new products at attractive prices. At least they appear to have found more than ever: "In addition, we have more new product...read more
5 stars

RE:RE:RE:RE:Diluted EPS up 69%

You have to be careful comparing Q4 to Q3 because of the rather large, lumpy foreign pharma sales amount in Q3. In 2013, RX had int'l sales in just one quarter. In 2014, they had sales in 2 quarters...read more
1 star

?????

Did they lose $0.22??  A misprint:)  No hope for RX?  rate and reply
5 stars

RE:RE:RE:Diluted EPS up 69%

Basher Sir_Holler wrote: Significant decline in year-over-year growth rate, revenues, gross profit, and after-tax profit vs. Q3 2014. ... Product introductions are lumpy so not wise to compare quarter...read more
1 star

RE:RE:Diluted EPS up 69%

Significant decline in year-over-year growth rate, revenues, gross profit, and after-tax profit vs. Q3 2014.  rate and reply
5 stars

RE:Diluted EPS up 69%

Products in market set to double. MD&A says: "To summarize, there are currently two products in Growth stage, two products in Launch phase - FeraMAX ® Powder and RepaGyn ®, two products in the Pre...read more
5 stars

Diluted EPS up 69%

"2014 marked our fifth consecutive year of greater than 50% top-line growth" commented René Goehrum, President and CEO of BioSyent. "With four launch phase products and two in growth phase, we have...read more
0 stars

RE:RE:Wise move would be to ....

lscfa: Maybe we're being a little harsh on poor old biloshi.  Let's look at a few Venture Exchange examples (from my portfolio)... CZO is getting obliter...just a minute, it's up 400+% in the past...read more
3.5 stars

RE:Wise move would be to ....

wrong. RX target price $13.25, up 32.5% from current price GUD target price $8.33 down 12% from current price  rate and reply
0 stars

RE:Wise move would be to ....

biloshi: So, I guess we can assume you've done the "wise" thing and moved on.  See you later...  rate and reply
1 star

Wise move would be to ....

Sell RX and buy GUD. Consider that RX is listed on the Venture and continues to linger .It appears that RX management is in no hurry to uplist. Just like real estate , location, location! GUD is...read more
0 stars

GUD looking to surpass RX....

Jan. 07, 2015  -------------------------->  Today: V.RX                      $10.95                                                  $10.07        DOWN  88 cents T.GUD                  $  7.66      ...read more
0 stars

Analyst Recommendation

Second stock in the clip. As can be seen, he finds it a bit too illiquid to include it in his fund but said that individuals should go out and buy it. GLTA http://www.bnn.ca/Video/player.aspx?vid...read more